- Home
- Profiles


John E Levine, MD
Pediatrics, Pediatric Hematology-Oncology
- About Me
- Clinical Focus
- Education & Certifications
- Awards
- Research
- Locations
- Insurance
- Publications
- Industry Relationships
About Me
My clinical practice focuses exclusively on patients (both adult and pediatric) who undergo Bone Marrow Transplant (BMT) and overlaps with my clinical research. I have designed, conducted, analyzed, and authored multiple clinical trials and data analyses of clinical GVHD, specifically, and clinical BMT, broadly. My long term goal is to improve outcomes for patients who undergo BMT by designing and conducting high impact clinical trials.
I co-direct the Mount Sinai Acute GVHD International Consortium [MAGIC] with James Ferrara, MD. This international consortium provides the opportunity to develop and test innovative treatment approaches for allogeneic BMT patients.
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
About Me
My clinical practice focuses exclusively on patients (both adult and pediatric) who undergo Bone Marrow Transplant (BMT) and overlaps with my clinical research. I have designed, conducted, analyzed, and authored multiple clinical trials and data analyses of clinical GVHD, specifically, and clinical BMT, broadly. My long term goal is to improve outcomes for patients who undergo BMT by designing and conducting high impact clinical trials.
I co-direct the Mount Sinai Acute GVHD International Consortium [MAGIC] with James Ferrara, MD. This international consortium provides the opportunity to develop and test innovative treatment approaches for allogeneic BMT patients.
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
About Me
My clinical practice focuses exclusively on patients (both adult and pediatric) who undergo Bone Marrow Transplant (BMT) and overlaps with my clinical research. I have designed, conducted, analyzed, and authored multiple clinical trials and data analyses of clinical GVHD, specifically, and clinical BMT, broadly. My long term goal is to improve outcomes for patients who undergo BMT by designing and conducting high impact clinical trials.
I co-direct the Mount Sinai Acute GVHD International Consortium [MAGIC] with James Ferrara, MD. This international consortium provides the opportunity to develop and test innovative treatment approaches for allogeneic BMT patients.
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
Clinical Focus
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Adult Non-Hodgkin's Lymphoma
- Bone Marrow Transplantation
- Hematologic Malignancies
- Hematologic Malignancies, Pediatric
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Adult Non-Hodgkin's Lymphoma
- Bone Marrow Transplantation
- Hematologic Malignancies
- Hematologic Malignancies, Pediatric
Education
MD, Eastern Virginia Medical School
Residency, Pediatrics
Children's Hospital of Los Angeles
Fellowship, Pediatric Hematology-Oncology
Memorial Sloan-Kettering Cancer Center
Awards
2013
Chair, Pediatric Scientific Interest Group, ASBMT Annual Meeting
2012
Chair, Scientific Program, ASBMT Annual Meeting
2007
Best Doctors in America
2005
Ford Motor Company Leadership in Health Award
Research
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
- Ruttenberg Treatment Center1470 Madison Avenue, 3rd Floor, New York, NY, 10029
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Affinity Medicaid-Medicare-Essential Exchange
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Cigna - Medicare
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - HealthPlus Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Hotel Trades
- Magnacare-Health Care
- Medicare - NJ
- Medicare - NY
- Metroplus
- Multiplan PHCS
- NJ Medicaid
- NY Medicaid
- Oxford - Freedom & Liberty
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Community Care Medicaid
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VNSNY Select Health Medicaid
- WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use. Daniela Weber, Markus Weber, Elisabeth Meedt, Sakhila Ghimire, Daniel Wolff, Matthias Edinger, Hendrik Poeck, Andreas Hiergeist, André Gessner, Francis Ayuk, Wolf Roesler, Matthias Wölfl, Sabrina Kraus, Robert Zeiser, Hannah Bertrand, Peter Bader, Evelyn Ullrich, Matthias Eder, Sigrun Gleich, Rachel Young, Wolfgang Herr, John E. Levine, James L.M. Ferrara, Ernst Holler. Blood advances
- Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study. Santosh Putta, Bradford A. Young, John E. Levine, Ran Reshef, Ryotaro Nakamura, Christopher Strouse, Miguel Angel Perales, Alan Howard, Polly Pine, Ju Shi, Peixin Zhang, Vincent T. Ho, Wael Saber. Transplantation and Cellular Therapy
- Effective treatment of low-risk acute GVHD with itacitinib monotherapy. Aaron Etra, Alexandra Capellini, Amin Alousi, Monzr M. Al Malki, Hannah Choe, Zachariah DeFilipp, William J. Hogan, Carrie L. Kitko, Francis Ayuk, Janna Baez, Isha Gandhi, Stelios Kasikis, Sigrun Gleich, Elizabeth Hexner, Matthias Hoepting, Urvi Kapoor, Steven Kowalyk, Deukwoo Kwon, Amelia Langston, Marco Mielcarek, George Morales, Umut Özbek, Muna Qayed, Ran Reshef, Wolf Rösler, Nikolaos Spyrou, Rachel Young, Yi Bin Chen, James L.M. Ferrara, John E. Levine. Blood
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Levine during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Equillium
- Symbio Pharmaceuticals
- Kamada
- Brennan Burtker
- Incyte Corporation
- Bluebird Bio
- Talaris
- Mallinckrodt
- Editas
- Novartis
- Jazz
- Falk, Waas
- Mesoblast Ltd.
- X4 Pharmaceuticals
Royalty Payments:
- ViraCor-IBT
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.